For type 2 diabetes mellitus. ANDA 203499, held by Zydus Pharms. Glipizide.
As of Nov 16, 2026, ANDA 203499 (Glipizide), held by Zydus Pharms, was first approved by FDA on Jul 16, 2018, with 1 approved supplement and 0 published complete response letters.
Glipizide extended-release tablets is a sulfonylurea indicated as an adjunct to diet and exercise to improve glycemic control in adults with type 2 diabetes mellitus Limitations of Use: Not for treatment of type 1 diabetes or diabetic ketoacidosis.
| Date | Submission | Status | Documents |
|---|---|---|---|
| Jul 16, 2018 | Original application | Approved | None posted |
| Oct 11, 2019 | Supplement 1Labeling · Standard review | Approved | None posted |
| Jul 16, 2018 | Original application | Approved | None posted |
Approvals, supplements, products and documents come from FDA's Drugs@FDA data files, refreshed daily; Drugs@FDA lists approved applications only. Complete response letters are FDA's published letters. Drugs@FDA and FDA complete response letters